Introduction
Pancreatic cancer is one of the most commonly diagnosed aggressive malignancies worldwide, with poor long-term prognosis. 1, 2 Patients with pancreatic carcinoma are often in the advanced stage and unresectable at the time of diagnosis, due to the difficulties in early diagnosis. Few of treatment options would be feasible for them. The latest report shows that pancreatic adenocarcinoma is the third cause of cancer-induced death worldwide, with a 5-year OS rate of 8%, while the survival is relatively better in the localized cases with the rate of 32%. 1 These patients with unresectable tumor lesions located in the celiac axis and the superior mesenteric artery without evidence of distant metastasis are defined as locally advanced pancreatic cancer (LAPC). Patients with LAPC account for ~30% of all the cases of pancreatic carcinoma, 3 with a median survival time of less than 10 months. 4 The front-line therapeutic options for LAPC patients are chemotherapy and radiotherapy, by which survival benefit is limited, and complications and adverse events (AEs) are frequent. Although some newer chemotherapy regimens like gemcitabine plus nab-paclitaxel, 5 dasatinib plus gemcitabine, 6 FOLFOX-6 7, 8 and FOLFIRINOX [9] [10] [11] appear and have shown a substantial survival benefit in patients with LAPC, the long-term prognosis is still poor and the heterogeneity between these studies is significant. 12 Therefore, an optimal treatment for LAPC patients should provide survival benefit, alleviate pain, improve quality of life, but not cause severe compactions.
High-intensity focused ultrasound (HIFU) is an emerging noninvasive ablation procedure which can ablate various solid tumors including LAPC. It can focus ultrasound energy on the target lesions and induce tumor coagulation necrosis by thermal effect. 13 Several clinical trials of HIFU palliative therapy for pancreatic carcinoma cases have provided promising results.
14,15 HIFU monotherapy [16] [17] [18] [19] [20] [21] or in combination with systemic chemotherapy 22, 23 has been proved to be able to relieve pain and might bring an additional survival benefit with rare severe AEs.
However, the efficacy of HIFU treatment remains to be confirmed by more research and clinical practice. This single-center, prospective, case series was performed to assess the clinical benefit and safety of HIFU treatment for LAPC cases.
Patients and methods Patients
From January 2014 to December 2016, cytologically or pathologically confirmed unresectable LAPC patients were eligible for treatment in our center. The inclusion criteria were as follows: patients with age ≥18 years; patients with adequate hepatic, renal, and bone marrow function (white blood cell ≥3.9×10 9 /L, absolute neutrophil count ≥1.5×10
9L
, platelets ≥100×10 9 /L, hemoglobin ≥10 g/dL, and serum creatinine ≤150 mmol/L); and patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1. In addition, some cases should be excluded including pregnancy, lactation, metabolic disease, prior cerebrovascular event, active second malignancy, and uncontrolled intermittent illness.
Each patient signed a document of informed consent before enrollment. The research obtained the approval of the ethics committee of Huadong Hospital affiliated to Fudan University and was done according to the Declaration of Helsinki.
Procedures
HIFU was performed using HIFUINT-9000 system (Shanghai A&S Sci-Tec Co., Ltd, Shanghai, China), which is a US-guided device. 22 Firstly, tumor location, size, and the morphological characteristics are identified by b-mode sonography, CT, or MRI; in the meantime, the influence of tumor on adjacent organs and blood vessels is also evaluated. Next, the detecting head of this system will complete the relocalization of the therapy area. Finally, the ablation energy focus is controlled to move sequentially along the threedimensional axis until the target lesion is totally covered. The main HIFU parameters of treatment in this study were the following: input power, 5-10 kW/cm 2 ; therapy depth, 2-15 cm; practice-focused sphere, 3 × 3 × 8 mm 
Observation and measurement
The primary outcome of this single-center, prospective cohort study was OS of patients. The secondary end points were 6-and 12-month survival rates, tumor response rate, carbohydrate antigen (CA) 19-9 response rate, VAS, quality of life, and safety. The evaluation of tumors was conducted by a CT or MRI scan before HIFU ablation, and at 1, 3, 6, and 12 months post-HIFU treatment. The response was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). 24 Serum levels of tumor biomarker CA 19-9 were measured before HIFU ablation and within 1 week after HIFU treatment, and CA 19-9 response was defined as >50% decline from baseline value. VAS pain scores and quality of life scores were also recorded and assessed before HIFU ablation, and at 1, 3, 6, and 12 months post-HIFU treatment. The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC-QLQ-C30) was adopted to evaluate the quality of life of patients. AEs were recorded, and the severity was graded in accordance with the Common Terminology Criteria for Adverse Events, version 4. OS analysis of patients was conducted by the Kaplan-Meier method. To obtain more detailed descriptions of the survival, stratified analyses by the characteristics of cases were also performed. Potential clinicopathological factors influencing the OS rates were evaluated by log-rank test (univariate analysis) and then by Cox proportional hazards model (multivariate analysis). All the data analyses were performed by Stata 12.0 software (StataCorp LP, College Station, TX, USA). A P-value <0.05 indicated statistical significance.
Results

Patient baseline characteristics
In total, 87 patients were enrolled in this study. The cases included 41 males and 36 females, with a median age of 68 years (range: 38-80 years). Median Karnofsky performance status (KPS) was 80; 58 cases had a KPS score ≥80 and 29 cases <80. The median VAS prior to HIFU was 3 (range: 0-8); 70.1% of the cases had a VAS ≥4. The mean of maximum diameter was estimated to be 3.7 cm (range: 1.7-6.9 cm); 41 cases had a mean diameter ≥3 cm and 46 cases <3 cm. A majority (91%) of the tumors were located in the head and body of the pancreas. Many patients received other therapies before enrollment, including chemotherapy (26), radiotherapy (6) , and surgery (12), however, some of them did not achieve remission, and others had relapsed in the short term. Details of the baseline characteristics of patients and tumors are described in Table 1 Figure 1 ).
Clinical response and Ca 19-9 response
Among 87 patients administrated with HIFU ablation, complete response (CR), partial response (PR), stable disease (SD), and progression disease (PD) were observed in 7, 25, Notes: (A) Before treatment, pancreatic cancer invaded local blood vessels. an irregular low-density mass with 2.6×3.0 cm could be seen in the head of the pancreas. The boundaries between the lesion and the hepatic artery, superior mesenteric vein, and the proximal end of the splenic vein were unclear, and the pancreatic duct was dilated. (B) One year after hiFU treatment, the pancreas atrophied, a small amount of pancreatic tissue was seen on the head of the pancreas, no obvious spaceoccupying lesions were seen, the gap of peripancreatic fat was clear, and there was no sign of pressure on the surrounding blood vessels. Abbreviations: hiFU, high-intensity focused ultrasound; laPC, locally advanced pancreatic cancer. Results obtained for tumor biomarker CA 19-9 are also presented in Table 3 . Patients achieved a CA 19-9 response at a median of 1 month (0.8-1.6). The mean nadir decrease from baseline was 4,077 U/mL. Nearly one-third of patients receiving HIFU treatment had a decrease exceeding 90% from the baseline level, and more than 50% of patients had a decrease exceeding 50% (Table 3) .
Vas pain score
The mean VAS pain assessment score was 4.62 (±SD 2.07) at baseline, and was 3.20 (±SD 1.21), 3.18 (±SD 1.02), 3.36 (±SD 1.24), and 3.79 (±SD 1.36) at 1, 3, 6, and 12 months after HIFU ablation, respectively. As shown in Figure 3 , a significant decrease from baseline levels (P<0.05) was observed at 1, 3, and 6 months post-HIFU therapy. Table 4 . Fatigue (14/87, 16.1%) is the most common AE, followed by abdominal pain (7/87, 8%), fever (7/87, 8%), nausea (5/87, 5.7%), and rash (4/87, 4.6%). Besides, elevated C-reactive protein levels, leucopenia and a subcutaneous nodule were reported by each of the two patients. It is worth mentioning that no patient complained of skin burns in our study. No cases of acute pancreatitis or peritonitis were observed during the follow-up period post-HIFU treatment. Moreover, no case withdrew from this research because of the side effects and no treatment-induced death was observed. higher score in both function and global health scales postconversion indicated an increased ability of patients to do daily activities. Meanwhile, high scores of symptom scales indicated suffering of the patients. The results are shown in Figure 4 . Global health status, physical function, emotional function, and cognitive function of patients were significantly (P<0.05) improved after HIFU treatment. Symptom scales revealed that fatigue and pain were significantly (P<0.05) reduced after HIFU therapy. 
Quality of life
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Discussion
Patients with unresectable LAPC are still in dire need of effective therapies, because of the limited efficacy of current therapeutic options. These treatments should improve patients' symptoms, relieve pain, and improve quality of life, rather than just achieving sufficient local tumor control. In this regard, HIFU ablation might be one of the appropriate therapies for patients with LAPC. During HIFU treatment, ultrasonic energy is focused on the target lesions, resulting in coagulative necrosis of lesions by thermal and cavitation effects. 26, 27 Moreover, HIFU treatment is reported to have the ability to enhance tumor immunity of patients. [28] [29] [30] HIFU ablation is an emerging therapy with encouraging clinical results. As reported by numerous studies, it could be applied in patients with advanced pancreatic carcinoma safely and effectively. 19, 31, 32 In clinical practice, HIFU combined with chemotherapy is preferred, but not HIFU alone. However, in the present study, the patients did not receive chemotherapy. They refused chemotherapy either because of AEs or medical expenses associated with chemotherapy or fear of relapse following chemotherapy. Zhou 14 overviewed 241 articles with a total of 653 cases on the HIFU monotherapy for LAPC and revealed that median OS was 10 months and pooled pain remission rate was 71.3% (Table 5) . The AEs associated with HIFU treatment were rare and tolerable, especially for patients of older age and with poor ECOG PS. Therefore, HIFU ablation could be considered as an optimal treatment for elderly cases and for those with low ECOG PS, who are unavailable for chemotherapy or radiotherapy.
In our subjects, the median OS was found to be 12.2 months, with 95% CI of 11.1-12.7 months. As a golden standard treatment for LAPC, patients undergoing first-line treatment with gemcitabine were reported to have a median OS of 5.6-9.2 months in numerous high-quality randomized controlled trials. [33] [34] [35] [36] [37] [38] [39] HIFU treatment might prolong the survival of patients to a greater extent, when compared with gemcitabine monotherapy. The 6-month and 12-month OS rates of 94.25% and 50.85%, respectively, in this study are comparable to the rates obtained with chemotherapy and radiotherapy in LAPC. 23, 40 In a study by Zhao et al 41 in 2017, the 6-month OS was found to be 44.4%-100% and 12-month OS was 11.1%-35.4% after HIFU treatment, which is numerically inferior to our results. Some factors such as sample size, statistical power, and baseline value might have contributed to this difference.
In terms of the AEs, during and after HIFU therapy, no serious adverse reactions were observed in this study. The treatment-related complication, as well as treatment cycle, was significantly reduced compared with chemotherapy or radiotherapy. 42, 43 However, recent reports have reported certain HIFU-related complications, especially skin burns, but our results did not show any evidence of complications due to skin burn. This can be attributed to the differences in the type of HIFU equipment used for treatment. HIFUNIT-9000 system used in this study adopts dual focus mode, and the energy upon the skin could be reduced effectively during operation compared with other equipment.
Several limitations of this study should be acknowledged. First, our results came from a single-center, non-blinded 
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hiFU treatment for laPC observation study, which would not provide the highest quality evidence of clinical practice. Second, our sample scale is relatively small, and the follow-up period is relatively short. Therefore, top-level designed trials with a larger sample size are needed. Nevertheless, our investigation has provided a reliable clinical evidence for the new direction of LAPC ablation treatment.
Conclusion
Our results further confirmed the efficacy and safety of HIFU treatment for patients with LAPC. HIFU might be one of the optimal therapies for LAPC. However, further well-designed double-blind, randomized controlled trials are warranted to evaluate the clinical efficacy of HIFU ablation, especially in combination with chemotherapy or radiotherapy.
